Practice Variations in the Use of Novel Oral Anticoagulants for Nonvalvular Atrial Fibrillation-Related Stroke among Stroke Neurologists in Saudi Arabia
Clinical trials have demonstrated that novel oral anticoagulants (NOACs) are noninferior to warfarin in preventing nonvalvular atrial fibrillation- (nvAF-) related stroke and systemic embolism. However, in these trials, NOACs initiation was delayed for a variable period after stroke. Herein, we aime...
Saved in:
Main Authors: | Mohammed H. Alanazy, Taim Muayqil |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Neurology Research International |
Online Access: | http://dx.doi.org/10.1155/2019/5373250 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation
by: Xue Zhou, et al.
Published: (2020-01-01) -
Apixaban in Comparison to Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
by: Muhammad U. Siddiqui, et al.
Published: (2019-01-01) -
The Role of Atrial Fibrillation and Oral Anticoagulation Status in Health‐Related Quality of Life 12 Months After Ischemic Stroke or TIA
by: Manuel C. Olma, et al.
Published: (2025-01-01) -
Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
by: Daisuke Fukamachi, et al.
Published: (2022-01-01) -
Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
by: Dana Prídavková, et al.
Published: (2019-01-01)